GET DAILY SIGNALSWhy Is AMN Healthcare Services (AMN) Stock Down -14.68% Today?
Key Takeaways
- Shares of AMN Healthcare Services fell 14.68% intraday to about $40.46, down from a prior close of $47.42.
- The decline came despite a Q3 2026 earnings and revenue beat, as investors focused on sharply weaker fourth-quarter profitability guidance.
- The Q3 beat was flattered by a $51 million favorable labor-disruption reserve adjustment rather than purely organic momentum.
- Fourth-quarter guidance implies an adjusted EBITDA margin of 5.8%–6.3% and roughly breakeven operating margin, pressuring sentiment.
- Analysts flagged valuation concerns, with one firm raising its price target but retaining an Underperform rating.
- Traders are watching bill-rate trends, international nurse visa timelines, and the pending Kaiser contract RFP.
- For more on this stock, explore Price Targets, Earnings, and Forecast data on Tickeron.
- Explore Trending AI Robots to see which AI-powered trading bots are performing best in current conditions.
Opening Summary
AMN Healthcare Services, Inc. (AMN) is a Dallas-based provider of technology-enabled healthcare workforce solutions and staffing services, operating across Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The stock is down 14.68% in today's session, trading near $40.46 versus a prior close of $47.42. The market reaction follows the company's third-quarter 2026 results, released after the close on November 5, which beat Wall Street estimates on both revenue and earnings but were overshadowed by a notably weaker fourth-quarter profit outlook.
Earnings Beat Undercut by Weak Forward Guidance
The primary driver of the selloff was forward guidance. AMN reported Q3 revenue of $717.3 million, up 13% year over year and above the roughly $648 million consensus, while adjusted EPS of $1.16 crushed the $0.22–$0.23 analyst estimate. Yet management guided fourth-quarter revenue to $655 million–$670 million, implying a double-digit year-over-year decline as labor-disruption revenue shrinks to about $5 million from prior elevated levels. More importantly, profitability guidance disappointed: gross margin of 25.7%–26.2%, adjusted EBITDA margin of just 5.8%–6.3%, and an operating margin near breakeven. That steep sequential margin compression is what rattled investors, overshadowing the headline beat.
Quality of the Q3 Beat Under Scrutiny
Analysts and investors also questioned the quality of the quarter's outperformance. A meaningful share of the upside came from a $51 million favorable reserve adjustment tied to prior labor-disruption events, which lifted reported gross margin to 31.9% and flattered adjusted EBITDA. Stripping out those one-time items, the underlying results were closer to the low end of guidance. The company also reported negative operating cash flow of about $88 million for the quarter as it refunded client deposits from earlier labor disruptions. While core travel nurse and allied volumes accelerated—travel nurse volume rose 21% year over year—the reliance on non-recurring reserve releases gave the market little reason to extrapolate the beat forward.
Analyst Reaction and Valuation Concerns
The post-earnings analyst commentary reinforced the cautious tone. BofA Securities raised its price target on AMN to $34.50 from $28.00, citing the strike-related strength, but kept an Underperform rating, arguing the current valuation already reflects an accelerating growth trajectory. The firm also trimmed its 2027 and 2028 EBITDA estimates on a lower starting point. Management additionally cut its international nurse outlook for a third consecutive quarter because of embassy visa appointment delays, adding another layer of near-term uncertainty to the growth story.
Market Context and Trading Activity
The decline in AMN was an earnings-driven, company-specific move rather than a broad sector or macro event. Trading volume was elevated relative to the stock's recent average as investors repriced shares following the report, and the move was sharp enough to push the stock back toward the lower end of its recent range, erasing a substantial portion of its recent gains. The divergence from broader healthcare staffing peers underscores that today's action was primarily a reaction to AMN's own guidance and the sustainability questions surrounding its margin profile.
What Comes Next for AMN
Looking ahead, investors will focus on whether bill rates stabilize after roughly 18 months of flat pricing and whether travel nurse and allied demand momentum carries into 2027. The company's international nurse segment faces ongoing visa-related headwinds, while the Kaiser contract is set to expire at year-end and is in a competitive RFP process—an outcome worth monitoring. On the positive side, leverage has improved to 1.3x from 3.3x a year earlier, and management pointed to a pipeline weighted toward managed-services opportunities and new vendor-management client wins onboarding for 2027. The balance between recovering core demand and fading one-time benefits will be the central question for the stock in the quarters ahead.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to compare approaches across different market environments. Explore the Trending AI Robots page to see which strategies are currently leading the field.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for AMN shows an upward move is likely
AMN's Aroon Indicator triggered a bullish signal on November 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 165 similar instances where the Aroon Indicator showed a similar pattern. In 137 of the 165 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMN advanced for three days, in 222 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for AMN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 18 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 65 cases where AMN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMN as a result. In 77 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for AMN turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 36 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
AMN moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.891) is normal, around the industry mean (204.220). P/E Ratio (13.305) is within average values for comparable stocks, (21.249). Projected Growth (PEG Ratio) (1.159) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.397) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of healthcare staffing and workforce services
Industry HospitalNursingManagement
Advertisement